Jacob A Udell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1150405/publications.pdf

Version: 2024-02-01

144 papers	10,290 citations	61857 43 h-index	34900 98 g-index
157 all docs	157 docs citations	157 times ranked	11676 citing authors

#	Article	IF	Citations
1	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 2013, 369, 1317-1326.	13.9	3,017
2	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	13.9	662
3	Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. Circulation, 2014, 130, 1579-1588.	1.6	594
4	Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients. JAMA - Journal of the American Medical Association, 2013, 310, 1711.	3.8	399
5	Sodium Glucose Cotransporter-2 Inhibition in Heart Failure. Circulation, 2017, 136, 1643-1658.	1.6	340
6	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal, 2016, 37, ehv443.	1.0	293
7	Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2015, 3, 356-366.	5.5	224
8	Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor. Circulation, 2018, 137, 1450-1459.	1.6	194
9	A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. New England Journal of Medicine, 2016, 374, 1145-1154.	13.9	191
10	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology, 2018, 34, 214-233.	0.8	181
11	Does This Patient With Liver Disease Have Cirrhosis?. JAMA - Journal of the American Medical Association, 2012, 307, 832.	3.8	146
12	The Cardiovascular Health in Ambulatory Care Research Team (CANHEART). Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 204-212.	0.9	143
13	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 696-705.	4.3	141
14	Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ: British Medical Journal, 2018, 363, k4209.	2.4	138
15	Influenza Vaccination in Patients WithÂChronic Heart Failure. JACC: Heart Failure, 2016, 4, 152-158.	1.9	112
16	Living Alone and Cardiovascular Risk in Outpatients at Risk of or With Atherothrombosis. Archives of Internal Medicine, 2012, 172, 1086.	4.3	109
17	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 418-435.	5.5	105
18	The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitusâ€“Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. American Heart Journal, 2011, 162, 818-825.e6.	1.2	98

#	Article	IF	Citations
19	Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure. JAMA Cardiology, 2019, 4, 363.	3.0	97
20	Heart failure outcomes in clinical trials of glucoseâ€lowering agents in patients with diabetes. European Journal of Heart Failure, 2017, 19, 43-53.	2.9	91
21	Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2014, 63, 2421-2428.	1.2	84
22	Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2018, 3, 155.	3.0	78
23	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2016, 1, 989.	3.0	77
24	Long-Term Cardiovascular Risk in Women Prescribed Fertility Therapy. Journal of the American College of Cardiology, 2013, 62, 1704-1712.	1.2	71
25	Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. European Heart Journal, 2020, 41, 86-94.	1.0	71
26	Myocardial Injury Pattern at MRI in COVID-19 Vaccineâ€“Associated Myocarditis. Radiology, 2022, 304, 553-562.	3.6	70
27	Cardiovascular Risk Following FertilityÂTherapy. Journal of the American College of Cardiology, 2017, 70, 1203-1213.	1.2	69
28	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2021, 325, 39.	3.8	65
29	Response to Letter Regarding Article, â€œHeart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trialâ€. Circulation, 2015, 132, e121-2.	1.6	61
30	Association of Influenza Vaccination With Cardiovascular Risk. JAMA Network Open, 2022, 5, e228873.	2.8	61
31	Frailty and Outcomes After Myocardial Infarction: Insights From the CONCORDANCE Registry. Journal of the American Heart Association, 2018, 7, e009859.	1.6	60
32	Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 1777-1794.	1.2	57
33	Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020. Canadian Journal of Neurological Sciences, 2022, 49, 315-337.	0.3	57
34	Use of sodiumâ€“glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. Cmaj, 2020, 192, E351-E360.	0.9	53
35	Outcomes of Women and Men With Acute Coronary Syndrome Treated With and Without Percutaneous Coronary Revascularization. Journal of the American Heart Association, 2017, 6, .	1.6	52
36	Next Steps in Primary Prevention of Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 66, 1828-1836.	1.2	50

#	Article	IF	Citations
37	Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists. Circulation, 2016, 134, 1915-1917.	1.6	50
38	Failure of fertility therapy and subsequent adverse cardiovascular events. Cmaj, 2017, 189, E391-E397.	0.9	49
39	Effect of the Women's Health Initiative on Osteoporosis Therapy and Expenditure in Medicaid. Journal of Bone and Mineral Research, 2006, 21, 765-771.	3.1	48
40	Patent Foramen Ovale Closure vs Medical Therapy for Stroke Prevention: Meta-analysis of Randomized Trials andÂReview of Heterogeneity in Meta-analyses. Canadian Journal of Cardiology, 2014, 30, 1216-1224.	0.8	48
41	Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Diabetes and MultivesselÂCoronary Disease. Journal of the American College of Cardiology, 2020, 76, 1153-1164.	1.2	48
42	Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American Heart Journal, 2022, 253, 86-98.	1.2	48
43	Improving the Appropriate Use of Transthoracic Echocardiography. Journal of the American College of Cardiology, 2017, 70, 1135-1144.	1.2	47
44	Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)â€TIMI 53 trial. Diabetes/Metabolism Research and Reviews, 2013, 29, 417-426.	1.7	46
45	Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 604-612.	1.1	45
46	Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Canadian Journal of Cardiology, 2021, 37, 1629-1634.	0.8	45
47	Clinical Trial Participation After Myocardial Infarction in a National Cardiovascular Data Registry. JAMA - Journal of the American Medical Association, 2014, 312, 841.	3.8	44
48	Regional variations in ambulatory care and incidence of cardiovascular events. Cmaj, 2017, 189, E494-E501.	0.9	44
49	Cardiovascular Protection in People With Diabetes. Canadian Journal of Diabetes, 2018, 42, S162-S169.	0.4	44
50	Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiology: Cardiothoracic Imaging, 2021, 3, e210252.	0.9	44
51	Sustained sexâ€based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. Clinical Cardiology, 2018, 41, 758-768.	0.7	43
52	The Association of Frailty With In-Hospital Bleeding Among Older AdultsÂWith Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2018, 11, 2287-2296.	1.1	42
53	Klotho, fibroblast growth factorâ€23, and the reninâ€“angiotensin system â€” an analysis from the PEACE trial. European Journal of Heart Failure, 2019, 21, 462-470.	2.9	41
54	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 2058-2068.	1.2	41

#	Article	IF	Citations
55	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. American Heart Journal, 2018, 202, 97-103.	1.2	38
56	Concomitant Administration of Clopidogrel With Statins or Calcium-Channel Blockers. JACC: Cardiovascular Interventions, 2013, 6, 1275-1281.	1.1	37
57	Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Metaâ€analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2015, 4, .	1.6	36
58	The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. Trends in Cardiovascular Medicine, 2017, 27, 194-202.	2.3	34
59	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome. JAMA Cardiology, 2018, 3, 473.	3.0	33
60	Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. Diabetes Care, 2018, 41, 2330-2338.	4.3	32
61	Calibration and discrimination of the Framingham Risk Score and the Pooled Cohort Equations. Cmaj, 2020, 192, E442-E449.	0.9	31
62	Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel. Journal of the American College of Cardiology, 2014, 63, 225-232.	1.2	30
63	Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004054.	0.9	30
64	Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 76, 1440-1450.	1.2	29
65	Cardiovascular Risk Factor Management Performance in Canada and the United States: A Systematic Review. Canadian Journal of Cardiology, 2017, 33, 393-404.	0.8	27
66	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes Care, 2022, 45, 204-212.	4.3	25
67	Cardiac MRI and Clinical Follow-up in COVID-19 Vaccineâ€“associated Myocarditis. Radiology, 2022, 304, E48-E49.	3.6	25
68	Valvular heart disease in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 507-518.	1.4	23
69	Pregnancy Complications in Women With Heart Disease Conceiving With Fertility Therapy. Journal of the American College of Cardiology, 2014, 64, 1862-1864.	1.2	22
70	Population Impact of Generic Valsartan Recall. Circulation, 2020, 141, 411-413.	1.6	22
71	Traditional Cardiovascular Risk Factors and the Presence of Obstructive Coronary Artery Disease in Men and Women. Canadian Journal of Cardiology, 2014, 30, 820-826.	0.8	21
72	Association of Cognitive Impairment With Treatment and Outcomes inÂOlder Myocardial Infarction Patients: A Report From the NCDRÂChest Painâ€“MI Registry. Journal of the American Heart Association, 2019, 8, e012929.	1.6	21

#	Article	IF	Citations
73	Anticoagulation after Anterior Myocardial Infarction and the Risk of Stroke. PLoS ONE, 2010, 5, e12150.	1.1	20
74	Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention. JAMA Cardiology, 2019, 4, 1160.	3.0	20
75	Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Clinical Cardiology, 2012, 35, 722-729.	0.7	19
76	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2016, 133, 2094-2098.	1.6	19
77	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. International Journal of Cardiology, 2017, 244, 24-29.	0.8	19
78	Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004983.	0.9	19
79	No Need to Sugarcoat the Message: Is Cardiovascular RiskÂReduction From SGLT2ÂInhibition Related to Natriuresis?. American Journal of Kidney Diseases, 2016, 68, 349-352.	2.1	18
80	Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. European Journal of Preventive Cardiology, 2014, 21, 1531-1540.	0.8	17
81	Does influenza vaccination influence cardiovascular complications?. Expert Review of Cardiovascular Therapy, 2015, 13, 593-596.	0.6	17
82	Design and methods of the Echo WISELY (Will Inappropriate Scenarios for Echocardiography Lessen) Tj ETQq0 0 0 rgBT /Overlock 10 Tf intervention to reduce inappropriate echocardiograms. American Heart Journal, 2015, 170, 202-209.	1.2	17
83	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med, 2021, 2, 1203-1230.	2.2	17
84	Comparable Benefit of Î²-Blocker Therapy in Heart Failure Across Regions of the World: Meta-analysis of Randomized Clinical Trials. Canadian Journal of Cardiology, 2014, 30, 898-903.	0.8	15
85	Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. American Journal of Cardiology, 2016, 117, 754-759.	0.7	15
86	Acute Decompensated HeartÂFailure in the Setting of Acute Coronary Syndrome. JACC: Heart Failure, 2022, 10, 404-414.	1.9	15
87	Inequitable distribution of implantable cardioverter defibrillators in Ontario. International Journal of Technology Assessment in Health Care, 2007, 23, 354-361.	0.2	14
88	Antiarrhythmic therapy as an adjuvant to promote post pulmonary vein isolation successâ€"a meta-analysis. Journal of Interventional Cardiac Electrophysiology, 2016, 47, 171-176.	0.6	14
89	Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study. Endocrinology, Diabetes and Metabolism, 2020, 3, e00096.	1.0	14
90	Primary and secondary prevention of heart failure with statins. Expert Review of Cardiovascular Therapy, 2006, 4, 917-926.	0.6	13

#	Article	IF	Citations
91	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. Heart, 2016, 102, 1396-1402.	1.2	13
92	Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events. Cmaj, 2020, 192, E302-E311.	0.9	13
93	Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. European Journal of Preventive Cardiology, 2022, 28, 1795-1806.	0.8	13
94	Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. Cardiovascular Research, 2022, 118, 1103-1114.	1.8	13
95	Am I Getting the Influenza Shot Too?: Influenza Vaccination as Postâ€"Myocardial Infarction Care for the Prevention of Cardiovascular Events and Death. Circulation, 2021, 144, 1485-1488.	1.6	13
96	Preoperative Intraaortic Balloon Pump Improves Early Outcomes Following High-Risk Coronary Artery Bypass Graft Surgery: A Meta-Analysis of Randomized Trials and Prospective Study Design. Journal of Invasive Cardiology, 2018, 30, 2-9.	0.4	13
97	Projected Realâ€World Effectiveness of Using Aggressive Lowâ€Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada. Journal of the American Heart Association, 2018, 7, .	1.6	11
98	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). American Journal of Cardiology, 2018, 122, 944-951.	0.7	11
99	High-Sensitivity Cardiac Troponinâ€"Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women (CODE-MI): Rationale and design for a multicenter, stepped-wedge, cluster-randomized trial. American Heart Journal, 2020, 229, 18-28.	1.2	11
100	Statins and SARSâ€CoVâ€2 Infection: Results of a Populationâ€Based Prospective Cohort Study of 469Â749 Adults From 2 Canadian Provinces. Journal of the American Heart Association, 2021, 10, e022330.	1.6	11
101	Comparison of Readmission and Death Among Patients With Cardiac Disease in Northern vs Southern Ontario. Canadian Journal of Cardiology, 2019, 35, 341-351.	0.8	10
102	Clinical outcomes for chest pain patients discharged home from emergency departments using high-sensitivity versus conventional cardiac troponin assays. American Heart Journal, 2020, 221, 84-94.	1.2	10
103	Myocarditis Following COVID-19 Vaccination. Cardiology Clinics, 2022, 40, 375-388.	0.9	10
104	Inhibition of the Renin-Angiotensin System Reduces the Rise in Serum Aldosterone in Acute Coronary Syndrome Patients with Preserved Left Ventricular Function: Observations from the AVANT GARDE-TIMI 43 Trial. Clinical Chemistry, 2013, 59, 959-967.	1.5	9
105	Exploring medically-related Canadian summer student research programs: a National Cross-sectional Survey Study. BMC Medical Education, 2019, 19, 140.	1.0	9
106	Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry. American Heart Journal, 2019, 214, 184-193.	1.2	8
107	Influenza vaccination: a â€˜shotâ€™ at INVESTing in cardiovascular health. European Heart Journal, 2021, 42, 2015-2018.	1.0	8
108	Sodiumâ€Glucose Cotransporter 2 Inhibitors, Allâ€Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Metaâ€Analysis and Metaâ€Regression. Journal of the American Heart Association, 2021, 10, e019918.	1.6	8

#	Article	IF	Citations
109	The risk of death or unplanned readmission after discharge from a COVID-19 hospitalization in Alberta and Ontario. Cmaj, 2022, 194, E666-E673.	0.9	8
110	Clinical risk, sociodemographic factors, and SARS-CoV-2 infection over time in Ontario, Canada. Scientific Reports, 2022, 12, .	1.6	8
111	Patient Preferences and the Ironic Nature of Randomized Trials. Medical Decision Making, 2011, 31, 226-228.	1.2	7
112	Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT). Clinical Cardiology, 2018, 41, 285-292.	0.7	7
113	Gaining Efficiency in Clinical Trials With Cardiac Biomarkers. Journal of the American College of Cardiology, 2021, 77, 1922-1933.	1.2	7
114	Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination. Current Atherosclerosis Reports, 2021, 23, 78.	2.0	7
115	A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes. Canadian Journal of Kidney Health and Disease, 2022, 9, 205435812210812.	0.6	7
116	Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest. American Journal of Cardiology, 2018, 121, 294-300.	0.7	6
117	Comparison of Cardiovascular Risk Factors and Outcomes Among Practicing Physicians vs the General Population in Ontario, Canada. JAMA Network Open, 2019, 2, e1915983.	2.8	6
118	Eligibility of sodiumâ€“glucose coâ€transporterâ€2 inhibitors among patients with diabetes mellitus admitted for heart failure. ESC Heart Failure, 2020, 7, 275-279.	1.4	6
119	Lipid-Lowering Therapy and Outcomes in Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2007, 12, 27-35.	1.0	5
120	Cardiac Presentation of Anaplastic Large-Cell Lymphoma. Journal of Clinical Oncology, 2010, 28, e314-e316.	0.8	5
121	Association Between Transthoracic Echocardiography Appropriateness and Echocardiographic Findings. Journal of the American Society of Echocardiography, 2019, 32, 667-673.e4.	1.2	5
122	Moving Toward Sex-Specific Cardiovascular Risk Estimation. Canadian Journal of Cardiology, 2020, 36, 13-15.	0.8	5
123	Universal flu vaccines: a shot at lifelong cardioprotection?. Nature Reviews Cardiology, 2022, 19, 145-146.	6.1	5
124	The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study. Thrombosis Research, 2022, 211, 114-122.	0.8	5
125	Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007903.	0.9	5
126	A Web-Based Health Application to Translate Nutrition Therapy for Cardiovascular Risk Reduction in Primary Care (PortfolioDiet.app): Quality Improvement and Usability Testing Study. JMIR Human Factors, 2022, 9, e34704.	1.0	5

#	Article	IF	Citations
127	Preexisting frailty and outcomes in older patients with acute myocardial infarction. American Heart Journal, 2022, 249, 34-44.	1.2	4
128	Heart Failure after Laboratory Confirmed Influenza Infection (FLU-HF). Global Heart, 2022, 17, .	0.9	4
129	Academic Practice Plans for EarlyÂCareerÂClinician Investigators. Journal of the American College of Cardiology, 2015, 66, 1839-1841.	1.2	3
130	Improving Statin Noncompliance: If You Build It, Will They Come?. Canadian Journal of Cardiology, 2019, 35, 813-815.	0.8	3
131	Respiratory Tract Infections, Nonsteroidal Anti-inflammatory Drugs and Acute Myocardial Infarction: Is Understanding Interaction Between Risk Factors the Key to Personalizing Prevention?. Journal of Infectious Diseases, 2017, 215, 497-499.	1.9	2
132	Prevalence and Treatment of Familial Hypercholesterolemia and Severe Hypercholesterolemia in Older Adults in Ontario, Canada. CJC Open, 2022, 4, 739-747.	0.7	2
133	Relationship of frailty with excess mortality during the COVID-19 pandemic: a population-level study in Ontario, Canada. Aging Clinical and Experimental Research, 2022, 34, 2557-2565.	1.4	2
134	Response by Lytvyn et al to Letter Regarding Article, â€œSodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trialsâ€• Circulation, 2018, 137, 1984-1985.	1.6	1
135	Making Informed CHOICES: The Launch of a â€œBig Dataâ€•Pragmatic Trial to Improve Cholesterol Management and Prevent Heart Disease in Ontario. Healthcare Quarterly (Toronto, Ont), 2020, 22, 6-9.	0.3	1
136	Editorial commentary: Influenza vaccine as part of a heart disease armamentarium in the new cardio-respiratory virus era. Trends in Cardiovascular Medicine, 2021, 31, 321-322.	2.3	1
137	A feasibility study for CODE-MI: High-sensitivity cardiac troponinâ€“Optimizing the diagnosis of acute myocardial infarction/injury in women. American Heart Journal, 2021, 234, 60-70.	1.2	1
138	Statin Use for Primary Cardiovascular Disease Prevention is Low in Inflammatory Arthritis. Canadian Journal of Cardiology, 2022, , .	0.8	1
139	Using big data for cardiovascular health surveillance: Insights from 10.3 million individuals in the CANHEART cohort. Canadian Journal of Cardiology, 2022, , .	0.8	1
140	Effect of Duration of Statin Treatment on all Cause Mortality: A Meta-Analysis of Randomized Control Trials*. Journal of Clinical Lipidology, 2015, 9, 442.	0.6	0
141	Risk Profile of Clinical Trial Participantsâ€”Reply. JAMA - Journal of the American Medical Association, 2015, 313, 94.	3.8	0
142	Socioeconomics and Atherosclerosis. Journal of the American College of Cardiology, 2019, 74, 536-537.	1.2	0
143	Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 5, 470.	0.5	0
144	Comparison Of Centralized And Traditional Methods Of Heart Failure Hospitalization Endpoint Capture. Journal of Cardiac Failure, 2022, 28, S91.	0.7	0